The emergence of a novel pandemic human strain of influenza A (H1N1/09) has clearly demonstrated the need for flexible tools enabling the rapid development of new diagnostic methods.
served as a model to show the feasibility of the UPL approach for the expedited development of new diagnostic assays to detect emerging pathogens.
In April 2009, a new influenza A H1N1 virus strain (H1N1/09) was identified (1 ) . Despite preventive measures, this agent is continuing to spread. WHO consequently declared pandemic alert phase 6 in June 2009, indicating that a global pandemic is underway (2 ). Compared with seasonal influenza strains, the transmissibility of the new H1N1/09 virus is substantially higher (3 ) . In the majority of cases, however, disease severity has been mild, with low case fatalities (4 ) . Nevertheless, concerns still remain that the new virus will acquire virulence in a second wave of disease during the Northern Hemisphere winter season-a scenario observed in the severe 1918 influenza pandemic (5 ) . The ongoing pandemic demonstrates the need for flexible laboratory tools for the rapid development of diagnostic tests. Among currently available laboratory methods, reverse-transcription quantitative real-time PCR (RT-qPCR) 4 assays have proven to be most adequate for the laboratory-guided clinical diagnosis of influenza. RT-qPCR assays have largely replaced traditional virus culture and antigen-based methods (6 ) . The development of novel RT-qPCR assays for the detection of viral pathogens still remains a fairly complex process, where delivery time of assay components has a large impact on the generation of results. To expedite this process, we designed a set of RT-qPCR assays based on the Universal ProbeLibrary (UPL)-a collection of 165 presynthesized, fluorescence-labeled DNA/locked nucleic acid (LNA) hybrid hydrolysis probes-to detect the new pandemic H1N1/09 virus strain. We evaluated candidate primer/UPL-probe pairs with 28 known positive samples of European and Mexican origin.
Based on multiple alignments of published influenza A sequences (Supplemental Fig. S1 , which accompanies the online version of this article at www.clinchem. org/content/vol55/issue12), we chose target regions for PCR primers in the hemagglutinin (HA) and neuraminidase (NA) genes. We designed PCR primer pairs using the Assay Design Center web service (https:// qpcr.probefinder.com/roche3.html) and evaluated 14 PCR primer pairs and LNA probes (Table 1 ) in the present study.
We performed nucleic acid extraction with a MagNA Pure LC instrument and the MagNA Pure LC 
Brief Communications
Total Nucleic Acid Isolation Kit (Roche). Specimens comprised cell culture medium, native nasopharyngeal swabs, and nasal and throat washes. Nucleic acids were extracted from 200-L aliquots and eluted in 100 L elution buffer. Samples collected by swabs were resuspended in 1 mL of 0.9% NaCl solution before extraction.
To reverse-transcribe viral RNA, we used the Transcriptor First Strand cDNA Synthesis Kit (Roche) in a 20-L reaction volume including 10 L nucleic acid extract. A 25-L qPCR reaction contained 10 L cDNA, 400 nmol/L forward and reverse primers (0.
For the construction of in vitro transcribed RNA standards, we amplified partial HA and NA gene fragments from cDNA obtained from the German H1N1/09 index patient (7 ). Online Supplemental Table S1 lists the respective primer sequences, positions, and amplicon sizes. PCR products were ligated into pCRII-TOPO plasmid vectors (Invitrogen) and cloned into E. coli. We confirmed recombinant plasmids by sequencing on a model 3730xl sequencer (Applied Biosystems). RNA was transcribed in vitro (RiboMAX kit; Promega), purified, and subjected to DNase digestion (RNeasy mini kit; Qiagen). After spectrophotometric quantification, we generated a 10-fold dilution series of each transcript (10 8 -10 0 copies per reaction).
For the estimation of the linear range, amplification efficiency, and analytical sensitivity of the 4 bestperforming assays, we tested different concentrations of NA and HA transcripts. Triplicates were processed for 10 8 , 10 6 , 10 4 , and 10 2 copies per reaction and 6 replicates for 10 1 and 10 0 copies. To assess diagnostic specificity, we used influenza samples of human and animal origin (online Supplemental Table S2 ). We analyzed 10 respiratory samples collected in June 2009 from Mexican patients with confirmed H1N1/09 infection. cDNA was diluted by a factor of 4 and processed as described above. Ten confirmed (8 ) H1N1/ 09-positive and 18 negative respiratory samples were collected in our diagnostic laboratory between May and August 2009. Eight positive nasal swab samples from the German Reference Center for Influenza (Robert-Koch-Institute, Berlin, Germany) were also available for analysis.
We initially carried out all 14 UPL probe-based RT-qPCR assays with a diluted nucleic acid preparation (10 1 -10 2 copies per reaction) known to be positive for H1N1/09. Twelve of 14 assays detected H1N1/09 without the need for further optimization (Table 1) . We reviewed RT-qPCR quality characteristics (e.g., by comparison of quantification cycles, sigmoidal shape of the amplification curves, total level of the fluorescence signal, reproducibility of the results in replicates, stability of the baseline fluorescence level; data not shown) and chose assays 5, 8, 10, and 13 for further evaluation. The detailed results of these assays performed with 10-fold serial dilutions of each RNA control are provided in online Supplemental Fig. S2 . The linear range of the assays was defined by the viral RNA concentration range over which the relationship between the log of RNA copies per RT-qPCR reaction and the quantification cycle was linear. As shown in Fig. 1 , a linear relationship existed from 1.0 ϫ 10 1 up to at least 1.0 ϫ 10 8 RNA copies per PCR reaction for all 4 assays. Within the linear range, we calculated the best-fitting curve. Based on the slope of the curves, PCR efficiencies were 2.02 (102%, assay 5), 1.94 (94%, assay 8), 1.92 (92%, assay 10), and 2.03 (103%, assay 13). We analyzed 6 replicates of RNA standards containing 10 1 and 10 0 copies per reaction to estimate the analytical sensitivity of each assay. The detailed results of these experiments are provided in online Supplemental Table S3 . In brief, all 4 assays reliably detected all replicates containing 10 1 copies per PCR reaction. Assay 5 was most sensitive, followed by assay 13. Based on the shape of the amplification curves, calculated PCR efficiencies, and analytical sensitivity, all further experiments were run with assays 5 and 13. We evaluated the diagnostic specificity of the assays using precharacterized seasonal influenza A and B and avian influenza virus culture samples (online Supplemental Table S2 ) and observed no cross-reactivity. We tested 4 stored clinical samples positive for seasonal influenza A (2008/09 season), and all 4 samples were negative. No cross-reaction was observed with a set of other commonly encountered viral and bacterial pathogens (online Supplemental  Table S2 ).
We obtained data on the diagnostic performance of assays 5 and 13 with clinical specimens (online Supplemental Table S4 ) by processing a total of 28 precharacterized positive and 18 negative samples. All 10 diluted positive cDNA samples of respiratory material from Mexico were detected by both assays. Among the set of precharacterized H1N1/09 samples from our diagnostic laboratory, all 10 H1N1/09-positive samples tested positive and all 18 negative samples tested negative. All 8 throat and nasal swab samples precharacterized as H1N1/09-positive by the German Reference Centre for Influenza were positive. Taken together, these data demonstrate 100% agreement of the results generated with assays 5 and 13 in comparison to the respective H1N1/09 reference assays.
The Universal ProbeLibrary (Roche Applied Science) comprises 165 presynthesized dual-labeled fluorogenic probes for use in PCR assays. Each probe is a DNA/LNA chimera, where some nucleotides are substituted by a locked nucleic acid, an RNA derivative in which the ribose ring is constrained by a methylene linkage between the 2Ј-oxygen and the 4Ј-carbon (9, 10 ) . This conformation restriction increases thermal stability of duplexes (11 ) . Chimeric DNA/LNA probes can therefore be designed as octamers or nonamers to be used under standard PCR conditions. The sequence composition of the presynthesized probes reflects the most frequently encountered octamers and nonamers in sequence databanks. Accordingly, PCR assays targeting most biologic sequences can be established by choosing appropriate and specific forward and reverse primers. Conventional assay design and optimization in RT-qPCR still remains fairly time-consuming. Dual-labeled probes usually have the longest order-to-delivery times among the necessary assay components. In contrast, unmodified PCR primers are available by overnight synthesis and next-day delivery. In this work, we demonstrated that a set of 165 presynthesized LNA-based probes can be used to efficiently develop RT-qPCR assays for the diagnosis of novel pathogens as soon as an appropriate diagnostic marker sequence of the corresponding target organism is available. After having completed in silico assay design on day 1 followed by overnight primer synthesis, we were able to perform the first experiments on day 2.
In the current influenza pandemic, availability of rapid and reliable diagnostic tools for the identification of infected individuals remains crucial for surveillance and to support clinicians in the decision whether to initiate antiviral therapy in high-risk patients (12 ) . Antigen-based tests are incapable of meeting these demands because of their known suboptimal diagnostic sensitivity and specificity and inability to differentiate between influenza A strains (13 ) . RT-qPCR assays are the method of choice for the laboratory diagnosis of novel H1N1/09 infection. Several protocols for the detection of the H1N1/09 virus have been published, but validation data on these assays are still limited (14 -16 ) .
We report on UPL RT-qPCR assays that reliably detect the H1N1/09 influenza virus and can be used in combination with established broad-range influenza A PCR assays (17 ) . H1N1/09 served as a model to show the feasibility of the UPL approach for the expedited development of new diagnostic assays to detect emerging pathogens. 
